Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
SC 13G/AAmendment to a previously filed SC 13GNov 12, 2013View HTMLDownload DOCDownload PDFDownload XLS
FWPFree Writing ProspectusOct 9, 2013View HTMLDownload DOCDownload PDFDownload XLS
S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersOct 7, 2013View HTMLDownload DOCDownload PDFDownload XLS
UPLOADCorrespondence from the SEC to the FilerMay 23, 2013View HTMLDownload DOCDownload PDFDownload XLS
CORRESPCorrespondence from the Filer to the SECMay 20, 2013View HTMLDownload DOCDownload PDFDownload XLS
UPLOADCorrespondence from the SEC to the FilerMay 9, 2013View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderApr 2, 2013View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2013View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2013View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2013View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 13, 2013View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2013View HTMLDownload DOCDownload PDFDownload XLS

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information